Key study of Ketek drug may have included fraud, errors

05/1/2006 | Wall Street Journal, The

Sanofi-Aventis' respiratory infection drug Ketek has been linked to reports of severe liver damage, and now some documents are raising questions about possible fraud and errors in a clinical trial of the drug that was used in the application for FDA approval. The drug company defended the clinical trial and said Ketek is safe.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC